The Molecular Biology of HIV Latency

Adv Exp Med Biol. 2018:1075:187-212. doi: 10.1007/978-981-13-0484-2_8.

Abstract

HIV remains incurable due to the existence of a reservoir of cells that harbor intact integrated genomes of the virus in the absence of viral replication. This population of infected cells remains invisible to the immune system and is not targeted by the drugs used in the current antiretroviral therapies (cART). Reversal of latency by the use of inhibitors of chromatin-remodeling enzymes has been studied extensively in an attempt to purge this reservoir of latent HIV but has thus far not shown any success in clinical trials. The full complexity of latent HIV infection has still not been appreciated, and the gaps in knowledge prevent development of adequate small-molecule compounds that can effectively perturb this reservoir. In this review, we will examine the role of epigenetic silencing of HIV transcription, posttranscriptional regulation, and mRNA processing in promoting HIV-1 latency.

Keywords: Latency; Tat-P-TEFb; Transcriptional interference; mRNA processing.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents / pharmacology
  • Anti-HIV Agents / therapeutic use
  • Cell Nucleus / ultrastructure
  • Chromatin / chemistry
  • Chromatin / genetics
  • Epigenesis, Genetic
  • Gene Expression Regulation, Viral
  • Gene Silencing
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • HIV-1 / drug effects
  • HIV-1 / genetics
  • HIV-1 / physiology*
  • Humans
  • Promoter Regions, Genetic
  • RNA Polymerase II / metabolism
  • RNA Processing, Post-Transcriptional
  • RNA, Messenger / genetics
  • RNA, Untranslated / genetics
  • RNA, Viral / genetics
  • Transcription Factors / metabolism
  • Transcription, Genetic
  • Virus Integration
  • Virus Latency* / drug effects
  • Virus Latency* / physiology
  • Virus Replication

Substances

  • Anti-HIV Agents
  • Chromatin
  • RNA, Messenger
  • RNA, Untranslated
  • RNA, Viral
  • Transcription Factors
  • RNA Polymerase II